Acquisition of Drug Analysis Business
We have extended our testing capabilities with the purchase of the assets of TDDA Omega Laboratories. The sale encompasses all processes, technologies and equipment from TDDA Omega Laboratories, which will allow us to provide critical laboratory drug and urine testing services for The Drug Detection Agency (TDDA) and other clients. Hill Laboratories already has a trusted relationship with TDDA, that has been built on providing methamphetamine testing analysis for over a decade.
Hill Laboratories’ urinalysis will provide efficient and accurate workplace drug testing across a wide panel of drugs including cannabis, methamphetamines, and opioids. The sale allows The Drug Detection Agency to focus on its core competencies in creating safer workplaces such as providing mobile drug and alcohol testing, policy design, and drug and alcohol training and education services. We are excited to be adding a laboratory service that helps reduce the risk of workplace accidents, allows us to expand our service offering for existing and new clients, as well as ensuring the continuity, quality and timeliness for testing TDDA samples as their preferred lab partner.
TDDA Omega Laboratory operations are currently Auckland based but will move to Hill Laboratories’ Hamilton headquarters in late September 2020. In addition, Armin Kiani, Head of Toxicology and all lab equipment will move to the Hamilton location. All TDDA Omega laboratory staff have also been offered employment at our Hamilton headquarters. The equipment component of the sale includes two high-tech liquid chromatography/tandem mass spectrometry (LC/MS/MS) instruments, used for the simultaneous detection and quantification of drugs and metabolites in urine samples.
The completion of the sale continues a positive period of growth for Hill Laboratories, and we’re looking forward to incorporating TDDA along with other new additions to our testing portfolio.